700
Participants
Start Date
February 12, 2022
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
GRT-C901
A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
GRT-R902
A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
Atezolizumab
Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
Ipilimumab
Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
Fluoropyrimidine plus leucovorin
Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
Bevacizumab
Bevacizumab administered as maintenance therapy per standard of care.
NYU Langone Health, New York
Columbia University Irving Medical Center, New York
New York Cancer and Blood, Port Jefferson Station
Allegheny General Hospital, Pittsburgh
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia
American Oncology Partners of Maryland, PA, Bethesda
Virginia Cancer Specialists, Fairfax
University of Virginia, Charlottesville
Prisma Health, Greenville
Orlando Health, Orlando
University of Miami, Miami
Mount Sinai Comprehensive Cancer Center, Miami Beach
Miami Cancer Institute at Baptist Health South Florida (USOR site), Miami
Advanced Research (Oncology & Hemotology Associates of West Broward), Tamarac
Lynn Cancer Institute - Boca Raton Regional Hospital, Boca Raton
Tennessee Oncology - Sarah Cannon Research Institute, Nashville
Vanderbilt University Medical Center, Nashville
Norton Cancer Institute, Louisville
Christ Hospital Cancer Center, Cincinnati
Indiana University, Indianapolis
Barbara Ann Karmanos Cancer Institute, Detroit
Medical College of Wisconsin, Milwaukee
University of Illinois at Chicago, Chicago
University of Chicago, Chicago
University of Kansas Medical Center, Fairway
Highlands Oncology, Springdale
Texas Oncology - Dallas Sammons, Dallas
Baylor Scott and White, Temple
MD Anderson, Houston
Texas Oncology PA - USOR, Austin
Rocky Mountain Cancer Centers - USOR, Denver
Huntsman Cancer Institute at University of Utah, Salt Lake City
Banner MD Anderson, Gilbert
Comprehensive Cancer Centers of Nevada, Las Vegas
U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology, Los Angeles
University of California Los Angeles (UCLA), Santa Monica
University of California - Irvine (UCI), Orange
Northwest Cancer Specialists DBA Compass Oncology - USOR, Portland
Eastern CT Hematology and Oncology Associates (ECHO), Norwich
Astera Cancer Care, East Brunswick
Summit Health, Florham Park
Morristown Medical Center, Morristown
Rutgers, New Brunswick
Seattle Project Corporation
INDUSTRY